We are live on ! Find out more
O

OrbiMed Portfolio holdings

AUM $5.05B
1-Year Est. Return 125.28%
This Fund
S&P 500
This Quarter Est. Return
+9.12%
1 Year Est. Return
+125.28%
3 Year Est. Return
+334.72%
5 Year Est. Return
+344.07%
10 Year Est. Return
+2,748.76%
AUM
$5.39M
AUM Growth
-$132K
Cap. Flow
+$358M
Cap. Flow %
6,649.45%
Top 10 Hldgs %
30.62%
Holding
156
New
15
Increased
31
Reduced
31
Closed
25

Top Buys

Rank Stock Value
1
THRD
Third Harmonic Bio
THRD
+$104M
2
SRPT icon
Sarepta Therapeutics
SRPT
+$90.6M
3
TMO icon
Thermo Fisher Scientific
TMO
+$49.7M
4
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$47.8M
5
BLU
BELLUS Health Inc.
BLU
+$33.8M

Top Sells

Rank Stock Value
1
BHVN
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
+$81.3M
2
ARQT icon
Arcutis Biotherapeutics
ARQT
+$44.9M
3
ABBV icon
AbbVie
ABBV
+$28.7M
4
VTYX
Ventyx Biosciences
VTYX
+$23.6M
5
PCVX icon
Vaxcyte
PCVX
+$20.2M

Sector Composition

Rank Sector Weight
1 Healthcare 98.05%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
VECT
51
DELISTED
VectivBio Holding AG Ordinary Shares
VECT
$38.8K 0.72%
6,473,561
– –
JANX icon
52
Janux Therapeutics
JANX
$902M
$38.4K 0.71%
2,836,386
– –
IONS icon
53
Ionis Pharmaceuticals
IONS
$9.11B
$34K 0.63%
768,900
+315,500
+70% +$13.3M
THC icon
54
Tenet Healthcare
THC
$22.3B
$33.2K 0.62%
643,300
-13,000
-2% -$772K
SCPH
55
DELISTED
scPharmaceuticals
SCPH
$31.3K 0.58%
4,797,148
– –
TVTX icon
56
Travere Therapeutics
TVTX
$5.13B
$30.9K 0.57%
1,253,130
+480,930
+62% +$12.4M
RAPT
57
DELISTED
RAPT Therapeutics
RAPT
$30.1K 0.56%
156,384
+48,084
+44% +$9.1M
QURE icon
58
uniQure
QURE
$2.72B
$30K 0.56%
1,597,000
+722,151
+83% +$15.2M
ALPN
59
DELISTED
Alpine Immune Sciences Inc
ALPN
$29.4K 0.55%
4,081,592
– –
ALXO icon
60
ALX Oncology
ALXO
$262M
$27.5K 0.51%
2,871,000
+684,731
+31% +$7.98M
BHVN
61
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
$25.8K 0.48%
170,769
-548,265
-76% -$81.3M
TELA icon
62
TELA Bio
TELA
$30.9M
$25.8K 0.48%
3,027,542
– –
GRCL
63
DELISTED
Gracell Biotechnologies Inc. American Depositary Shares
GRCL
$25.4K 0.47%
7,884,870
– –
ETNB
64
DELISTED
89bio
ETNB
$21.2K 0.39%
3,658,869
– –
IOVA icon
65
Iovance Biotherapeutics
IOVA
$2.04B
$19.2K 0.36%
2,007,458
-790,983
-28% -$9.12M
GHRS icon
66
GH Research
GHRS
$1.89B
$18.8K 0.35%
1,622,060
– –
MGTX icon
67
MeiraGTx Holdings
MGTX
$1.08B
$17.7K 0.33%
2,108,143
-393,475
-16% -$3.47M
PCVX icon
68
Vaxcyte
PCVX
$7.72B
$17.2K 0.32%
717,900
-795,759
-53% -$20.2M
DBTX
69
DELISTED
Decibel Therapeutics, Inc. Common Stock
DBTX
$17.1K 0.32%
4,945,192
– –
IVVD icon
70
Invivyd
IVVD
$169M
$16.5K 0.31%
5,270,400
+214,400
+4% +$856K
KZR
71
DELISTED
Kezar Life Sciences
KZR
$15.3K 0.28%
177,170
+35,180
+25% +$3.42M
TSVT
72
DELISTED
2seventy bio
TSVT
$15.2K 0.28%
+1,041,300
New +$15.5M
KALV
73
DELISTED
KalVista Pharmaceuticals
KALV
$15.1K 0.28%
1,042,000
+856,600
+462% +$12M
NPCE icon
74
Neuropace
NPCE
$490M
$15K 0.28%
4,012,281
– –
VSTM icon
75
Verastem
VSTM
$520M
$14.6K 0.27%
+1,433,333
New +$20M
1 2
3
4 5

Similar funds

HSA
HBK Sorce Advisory Erie, Pennsylvania $5.05B AUM 16.64% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $5.06B AUM 91.14% 1-Year Est. Return
NL
NEPC LLC Boston, Massachusetts $5.02B AUM 7.87% 1-Year Est. Return
BPWM
Badgley Phelps Wealth Managers Seattle, Washington $5.02B AUM 21.87% 1-Year Est. Return
LFG
Lazard Frères Gestion Paris, France $5.07B AUM 20.66% 1-Year Est. Return
JIM
Jensen Investment Management Lake Oswego, Oregon $5.07B AUM 4.98% 1-Year Est. Return
CTC
Central Trust Company Jefferson City, Missouri $5.08B AUM 25.65% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return

OrbiMed's Q3 2022 Portfolio in Review

As of Q3 2022, OrbiMed held 156 positions worth $5.39M, down 2.4% from $5.52M the previous quarter. Its ten largest holdings account for 31% of the portfolio.

OrbiMed deployed $358M of net new capital in Q3 2022, opening 15 new positions and adding to 31 existing holdings. Its largest new stake was Third Harmonic Bio: 5,779,071 shares worth $110K.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, up from 98% a quarter earlier.

On the sell side, the largest reduction was Biohaven Pharmaceutical Holding Company Ltd., an estimated $81.3M trimmed.

  • OrbiMed's largest Q3 2022 buy was Third Harmonic Bio: 5,779,071 shares worth $110K.
  • OrbiMed added most to Sarepta Therapeutics in Q3 2022, an estimated $90.6M increase.
  • OrbiMed's biggest Q3 2022 reduction was Biohaven Pharmaceutical Holding Company Ltd., cutting an estimated $81.3M.
  • OrbiMed fully exited Horizon Therapeutics Public Limited Company Ordinary Shares in Q3 2022, selling an estimated $168K.
  • OrbiMed's ten largest holdings make up 31% of its $5.39M portfolio in Q3 2022.
  • OrbiMed opened 15 new positions and closed 25 in Q3 2022.
  • OrbiMed's portfolio value fell 2.4% quarter-over-quarter to $5.39M.

Based on OrbiMed's 13F filing for Q3 2022, filed 14 Nov 2022.